BridgeBio Oncology director receives option grant

BridgeBio Oncology Therapeutics director Praveen P. Tipirneni received a stock option grant for 31,675 shares of Common Stock.

Rhea-AI Filing Summary

BridgeBio Oncology Therapeutics director Praveen P. Tipirneni received a stock option grant for 31,675 shares of Common Stock. The option has an exercise price of $7.73 per share and expires on June 15, 2036. It vests in full on the earlier of the first anniversary of the grant date or the next Annual Meeting of Stockholders, subject to his continued service. Following this grant, he holds options for 31,675 shares directly, with no open-market buying or selling reported in this filing.

Insider Trade Summary

Grant/Award: 31,675 shares

Grant/Award 1 txn

Insider Tipirneni Praveen P.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	31,675	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 31,675 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.

Key Figures

Option Shares Granted: 31,675 shares Exercise Price: $7.73 per share Expiration Date: June 15, 2036 +1 more

4 metrics

Option Shares Granted 31,675 shares Stock Option (Right to Buy) grant to director

Exercise Price $7.73 per share Stock option exercise price for Common Stock

Expiration Date June 15, 2036 Option expiration for granted stock options

Shares Underlying Options After Grant 31,675 shares Total derivative shares following transaction

Key Terms

Stock Option (Right to Buy), Common Stock, exercise price, vest in full, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

exercise price financial

"conversion_or_exercise_price: 7.7300"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest in full financial

"The shares underlying the stock option vest in full upon the earlier"

Annual Meeting of Stockholders financial

"the date of the next Annual Meeting of Stockholders of the Issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did BBOT director Praveen P. Tipirneni report?

Director Praveen P. Tipirneni reported receiving a stock option grant for 31,675 shares of BridgeBio Oncology Therapeutics Common Stock. This was a compensation-related award, not an open-market share purchase or sale, and is recorded as a derivative acquisition.

What is the exercise price of the new BBOT stock options?

The granted stock options have an exercise price of $7.73 per share. This means Tipirneni can buy BridgeBio Oncology Therapeutics Common Stock at $7.73 if he exercises the options after they vest and before they expire.

When do Praveen Tipirneni’s BridgeBio Oncology options vest?

The options vest in full on the earlier of the first anniversary of the grant date or the next Annual Meeting of Stockholders. Vesting is conditioned on Tipirneni’s continued service to BridgeBio Oncology Therapeutics through the applicable vesting date.

When do the reported BBOT stock options expire?

The reported stock options expire on June 15, 2036. If they are not exercised by that expiration date, Tipirneni will lose the right to purchase BridgeBio Oncology Therapeutics shares at the $7.73 exercise price granted.

How many BBOT derivative securities does Tipirneni hold after this grant?

After this grant, Tipirneni holds stock options for 31,675 shares of BridgeBio Oncology Therapeutics Common Stock directly. The Form 4 does not show additional derivative positions, and there were no reported open-market buys or sells in this filing.

Is the BBOT Form 4 transaction a market buy or sell of shares?

No, the Form 4 reflects a grant of stock options, not a market trade. The transaction is coded as a grant or award acquisition (code A), meaning it is part of compensation rather than an open-market purchase or sale of BridgeBio Oncology Therapeutics shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/18/2026 - 04:59 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tipirneni Praveen P.

(Last) (First) (Middle)

BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.

256 EAST GRAND AVENUE, SUITE 104

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$7.73	06/16/2026		A		31,675		(1)	06/15/2036	Common Stock	31,675	$0	31,675	D

Explanation of Responses:

1. The shares underlying the stock option vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting of Stockholders of the Issuer following the date of grant, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Aaron Chan, Attorney-in-Fact	06/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)